Dexloxiglumide

Dexloxiglumide

Systematic (IUPAC) name
(4R)-4-[(3,4-dichlorobenzoyl)amino]-5-(3-methoxypropylpentylamino)-5-oxopentanoic acid
Identifiers
CAS Number	119817-90-2 Y
ATC code	None
PubChem	CID 65937
IUPHAR/BPS	889
ChemSpider	59342 N
UNII	69DY40RH9B N
ChEMBL	CHEMBL550781 N
Chemical data
Formula	C21H30Cl2N2O5
Molar mass	461.379 g/mol
SMILES CCCCCN(CCCOC)C(=O)[C@@H](CCC(=O)O)NC(=O)C1=CC(=C(C=C1)Cl)Cl
InChI InChI=1S/C21H30Cl2N2O5/c1-3-4-5-11-25(12-6-13-30-2)21(29)18(9-10-19(26)27)24-20(28)15-7-8-16(22)17(23)14-15/h7-8,14,18H,3-6,9-13H2,1-2H3,(H,24,28)(H,26,27)/t18-/m1/s1 N Key:QNQZBKQEIFTHFZ-GOSISDBHSA-N N
NY (what is this?)  (verify)

Dexloxiglumide is a drug which acts as a cholecystokinin antagonist, selective for the CCK_A subtype. It inhibits gastrointestinal motility and reduces gastric secretions, and despite older selective CCK_A antagonists such as lorglumide and devazepide having had only limited success in trials and ultimately never making it into clinical use, dexloxiglumide is being investigated as a potential treatment for a variety of gastrointestinal problems including irritable bowel syndrome,^[1] dyspepsia,^[2] constipation^[3] and pancreatitis,^[4][5] and has had moderate success so far although trials are still ongoing.

References

1. ↑ Cremonini F, Camilleri M, McKinzie S, Carlson P, Camilleri CE, Burton D, Thomforde G, Urrutia R, Zinsmeister AR. Effect of CCK-1 antagonist, dexloxiglumide, in female patients with irritable bowel syndrome: a pharmacodynamic and pharmacogenomic study. American Journal of Gastroenterology. 2005 Mar;100(3):652-63. PMID 15743365
2. ↑ Galligan JJ, Vanner S. Basic and clinical pharmacology of new motility promoting agents. Neurogastroenterology and Motility. 2005 Oct;17(5):643-53. PMID 16185302
3. ↑ Roberts DJ, Banh HL, Hall RI. Use of novel prokinetic agents to facilitate return of gastrointestinal motility in adult critically ill patients. Current Opinion in Critical Care. 2006 Aug;12(4):295-302. PMID 16810038
4. ↑ Maselli MA, Mennuni L. CCK1 receptor antagonist, dexloxiglumide: effects on human isolated gallbladder. Potential clinical applications. Minerva Gastroenterologica e Dietologica. 2003 Sep;49(3):211-6. PMID 16484960
5. ↑ Barrett TD, Yan W, Freedman JM, Lagaud GJ, Breitenbucher JG, Shankley NP. Role of CCK and potential utility of CCK1 receptor antagonism in the treatment of pancreatitis induced by biliary tract obstruction. British Journal of Pharmacology. 2008 Apr;153(8):1650-8. PMID 18297100